Listen to this Article Now
In a late-stage research, AstraZeneca’s investigational COVID-19 antibody medication combination reduced severe disease or death in non-hospitalized patients, the British pharma reported on Monday.
The medicine, AZD7442, lowered the risk of developing severe COVID-19 or mortality by half among patients who had been symptomatic for seven days or fewer, achieving the trial’s main target.
“An early intervention with our antibody can give a significant reduction in progression to severe disease, with continued protection for more than six months,” said Mene Pangalos, executive vice president, biopharmaceuticals R&D at AstraZeneca (NASDAQ:AZN).
The corporation will discuss the data with health authorities, it stated, without going into further detail. AstraZeneca is also working on developing the drug combination as a therapy for those who do not have a robust enough immune response to COVID-19 vaccinations.
Last Monday, it requested emergency permission from US regulators for its use as a preventive medicine.
Story by : Norvisi Mawunyegah